Securities code: 600668 securities abbreviation: Zhejiang Jianfeng Group Co.Ltd(600668) No.: pro 2022-001
Zhejiang Jianfeng Group Co.Ltd(600668)
Announcement on abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The company’s stock price has increased greatly in the short term, reminding investors to pay attention to transaction risks. Zhejiang Jianfeng Group Co.Ltd(600668) (hereinafter referred to as “the company”) shares deviated from the daily closing price by more than 20% in three consecutive trading days on January 12, 2022, January 13, 2022 and January 14, 2022, which constituted the abnormal fluctuation of stock trading specified in the trading rules of Shanghai Stock Exchange. The company’s stock price has increased greatly in the short term, reminding investors to pay attention to the transaction risk of the secondary market, make prudent decisions and invest rationally.
The controlling shareholder and actual controller of the company have no major matters involving the company. Through self-examination and verification with the controlling shareholders and actual controllers of the company, except for the information publicly disclosed on the designated media, there are no major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset divestiture, asset injection, share repurchase, equity incentive, bankruptcy reorganization, major business cooperation The introduction of strategic investors and other major issues.
The company belongs to non-metallic mineral products industry. At present, the company’s daily operation and external environment have not changed significantly. The company’s main business is still cement and medicine. According to the guidelines for Industry Classification of listed companies issued by the CSRC, the company belongs to the non-metallic mineral products industry (C30).
The profit of the company’s pharmaceutical sector decreased and Shanghai North Carolina lost money. From January to September 2021, the performance of the pharmaceutical sector of the company decreased. The holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Jianfeng pharmaceutical”) realized a net profit attributable to the parent of RMB 4.9701 million, a decrease of 83.09% over the same period of the previous year. The holding subsidiary of Jianfeng pharmaceutical Shanghai Beika Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Shanghai Beika”) realized a net profit attributable to the parent of RMB -16.7401 million, Compared with the same period last year, it decreased by 258.44%.
Caron anhydride will not have a significant impact on the overall operating performance of the company, and there may be the risk of oversupply and price decline. The sales revenue of caronic anhydride from Shanghai North Carolina accounts for a small proportion of the company’s total operating revenue and the gross profit margin is low, which will not have a significant impact on the company’s overall operating performance in 2021 and subsequent years. There are many chemical enterprises in China. If the supply of other enterprises in the industry increases or the downstream demand decreases in the future, it may lead to oversupply and price decline of Caron anhydride. Please pay attention to investment risks, make prudent decisions and invest rationally.
1、 Details of abnormal fluctuations in stock trading
The daily closing price of the company’s shares has deviated by more than 20% in three consecutive trading days on January 12, 2022, January 13, 2022 and January 14, 2022, which constitutes the abnormal fluctuation of stock trading specified in the trading rules of Shanghai Stock Exchange.
2、 Relevant information concerned and verified by the company
(I) production and operation
Through self inspection, the company’s daily operation and external environment have not changed significantly. The company’s main business is still cement and medicine, supplemented by health products, international trade, logistics, cables and other businesses. According to the guidelines for Industry Classification of listed companies issued by the CSRC, the company belongs to the non-metallic mineral products industry (C30). (II) major events
After sending a consultation letter to the controlling shareholder and actual controller of the company, it is confirmed that there is no major information that should be disclosed but not disclosed by the company, and there is no major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset divestiture, asset injection, share repurchase, equity incentive, bankruptcy reorganization, major business cooperation The introduction of strategic investors and other major issues.
(III) media reports, market rumors and hot concepts
Recently, many investors consulted the company through the telephone and e interactive platform and paid attention to the company’s Caron anhydride intermediate business, which may have the risk of speculation in the secondary market.
As of the disclosure date of this announcement, Shanghai North Carolina and its subsidiaries have mainly engaged in pesticide technical drugs and intermediates. The main varieties of intermediates are levofloxacin and oxyfluorocarboxylic acid. The sales volume of Caron anhydride is small and the gross profit margin is low. The sales revenue of Caron anhydride in 2021 is about 12.6037 million yuan, about 0.39% of the company’s total sales revenue in 2020; All sales customers are Chinese customers. According to the calculation of the company’s financial department, the sales gross profit margin of Caron anhydride is less than 5% (Unaudited), which is less than 0.1% of the company’s net profit in 2020. The Caron anhydride business will not have a significant impact on the overall operating performance of the company in 2021 and subsequent years.
At present, Shanghai North Carolina does not hold the production patent of “new synthesis method of uronic acid lactone, carbonic acid, carbonic anhydride and its key intermediates” (application No.: 2011102478118); The process route of the patent of “new synthesis method of Caron anhydride” (Patent No.: zl201010609467.8) held by Shanghai North Carolina has low yield and high cost.
(IV) other stock price sensitive information
The company has not found any other major events that may have a great impact on the company’s share price. The company’s directors, supervisors, senior managers, controlling shareholders and actual controllers did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Relevant risk tips
(I) secondary market transaction risk
The daily closing price of the company’s shares has deviated by more than 20% in three consecutive trading days on January 12, 2022, January 13, 2022 and January 14, 2022, which constitutes the abnormal fluctuation of stock trading specified in the trading rules of Shanghai Stock Exchange. The company’s stock price has increased greatly in the short term, reminding investors to pay attention to the transaction risk of the secondary market, make prudent decisions and invest rationally.
(II) risk of demand, supply and price change of Caron anhydride
There are many chemical enterprises in China. If the supply of other enterprises in the industry increases or the downstream demand decreases in the future, it may lead to oversupply and price decline of Caron anhydride. Please pay attention to investment risks, make prudent decisions and invest rationally.
(III) the sales revenue of caronic anhydride accounts for a relatively small proportion and the gross profit margin is low, which will not have a significant impact on the overall operating performance of the company
In 2021, the sales revenue of carbonic anhydride (alias: carbonic anhydride) of Shanghai North Carolina was about 12.7037 million yuan, about 0.39% of the company’s total sales revenue in 2020; The sales customers are all Chinese customers. According to the calculation of the company’s financial department, the sales gross profit margin of Caron anhydride is less than 5% (Unaudited), which is less than 0.1% of the company’s net profit in 2020, and will not have a significant impact on the company’s overall operating performance in 2021 and later years.
(IV) risk of performance decline of the company’s pharmaceutical sector
In recent years, the state has continuously deepened the reform of the medical and health system. With the continuous promotion of policies such as the two vote system, the consistency evaluation of generic drugs and the centralized procurement with volume, the price of drugs has decreased significantly and the growth rate of operating revenue of the pharmaceutical industry has decreased. In 2020, Jianfeng pharmaceutical achieved a net profit of 18.5885 million yuan, a decrease of 17.24% compared with 2019, and Shanghai North Carolina achieved a net profit of -25.4226 million yuan, a decrease of 35.22% compared with 2019. In the first three quarters of 2021, Jianfeng pharmaceutical realized a net profit attributable to its parent company of 4.9701 million yuan, a decrease of 83.09% over the same period of last year, and Shanghai North Carolina realized a net profit attributable to its parent company of -16.7401 million yuan, a decrease of 258.44% over the same period of last year. The decline in the operating performance of its subsidiaries Jianfeng pharmaceutical and Shanghai North Carolina had an adverse impact on the overall performance of the company.
4、 Board statement
The board of directors of the company confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules Information that may have a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
It is hereby announced
Zhejiang Jianfeng Group Co.Ltd(600668) online disclosure document of the board of directors on January 15, 2002
Written replies from controlling shareholders and actual controllers
